Q-omics provides the consensus-scored LINC01558 profile across patient tissues and cancer cell-line models. LINC01558 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, LINC01558 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LINC01558 RNA expression shows 14,932 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight OV, KIRC, and UVM as cancer lineages where LINC01558 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01558 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01558 survival associations across molecular data types. LINC01558 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01558 RNA expression–survival associations across cancer types. High LINC01558 expression shows unfavorable associations in OV, LUSC, ESCA and LGG, but favorable associations in UCS and KIRC. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify OV as the clearest survival context for LINC01558 RNA expression.
This table summarizes LINC01558 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01558. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01558 shows lower tumor expression in KIRC, KIRP, KICH, HNSC and LUSC and higher tumor expression in COAD. The KIRC box plot shows higher LINC01558 RNA expression in normal versus tumor tissue (log2 FC = −0.913, t-test p < 0.001).
This table shows molecular features associated with LINC01558 in patient tissues and cancer cell lines. In patient samples, LINC01558 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC01558 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
